CD8A and neoplasm: Reports showed dramatic tumor regression and metastatic inhibition after combined usage of anti-PD-1 antibody and oncolytic VACV in a previously treatment-refractory carcinoma model [145], with an increased CD8+ T cells infiltration and DC activation [47].